We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Final Adverse Event Guidance Recommends Aggregate Analysis
Final Adverse Event Guidance Recommends Aggregate Analysis
January 16, 2009
A final FDA guidance designed to curb unnecessary reporting of adverse events recommends that sponsors of multicenter clinical trials determine when an incident is serious, unanticipated and should be reported to an investigational review board (IRB).